Efficacy and safety of four dose regimes of a hypoallergenic recombinant birch pollen major allergen (rBet v 1-FV) in birch pollen allergic patients studied in an environmental exposure chamber

被引：0
|
作者：
Meyer, W. [1 ]
Narkus, A. [1 ]
Salapatek, A. [2 ]
Patel, D. [2 ]
Mussler, S. [1 ]
Haefner, D. [1 ]
机构：
[1] Allergopharma Joachim Ganzer KG, Dept Med, Reinbek, Germany
[2] Cetero Res, Med Affairs, Mississauga, ON, Canada
来源：
ALLERGY | 2012年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
187
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [1] Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial
    Klimek, Ludger
    Bachert, Claus
    Lukat, Karl-Friedrich
    Pfaar, Oliver
    Meyer, Hanns
    Narkus, Annemie
    CLINICAL AND TRANSLATIONAL ALLERGY, 2015, 5
  • [2] Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV results of 2 years of treatment (Phase II trial)
    Kettner, J.
    Meyer, H.
    Cromwell, O.
    Narkus, A.
    Jost, K.
    ALLERGY, 2007, 62 : 262 - 262
  • [3] Specific immunotherapy with recombinant birch pollen allergen rBet v 1-FV is clinically efficacious-results of a phase III study
    Kettner, J.
    Meyer, H.
    Narkus, A.
    Cromwell, O.
    Jost, K.
    ALLERGY, 2007, 62 : 33 - 33
  • [4] The recombinant hypoallergenic variant 'Bet v 1-FV' of the major birch allergen Bet v 1 is irreversibly unfolded
    Wald, M.
    Pump, L.
    Hagen, S.
    Suck, R.
    Cromwell, O.
    Nandy, A.
    ALLERGY, 2011, 66 : 141 - 141
  • [5] Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1
    Mahler, V
    Vrtala, S
    Kuss, O
    Diepgen, TL
    Suck, R
    Cromwell, O
    Fiebig, H
    Hartl, A
    Thalhamer, J
    Schuler, G
    Kraft, D
    Valenta, R
    CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (01): : 115 - 122
  • [6] Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients
    Nopp, A
    Halldén, G
    Lundahl, J
    Johansson, E
    Vrtala, S
    Valenta, R
    Grönneberg, R
    van Hage-Hamsten, M
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (01) : 101 - 109
  • [7] Skin response to recombinant birch pollen allergen (Bet v1a) in allergic patients during and out of the birch pollen season
    Brzezinska-Pawlowska, O.
    Lupinek, C.
    Piechota-Polanczyk, A.
    Kurowski, M.
    Jablonska, A.
    Stolz, F.
    Kopp, S.
    Neubauer, A.
    Kiss, R.
    Valenta, R.
    Kowalski, M. L.
    ALLERGY, 2015, 70 : 173 - 173
  • [8] Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1
    Vrtala, S
    Hirtenlehner, K
    Susani, M
    Akdis, M
    Kussebi, F
    Akdis, CA
    Blaser, K
    Hufnagl, P
    Binder, BR
    Politou, A
    Pastore, A
    Vangelista, L
    Sperr, WR
    Semper, H
    Valent, P
    Ebner, C
    Kraft, D
    Valenta, R
    FASEB JOURNAL, 2001, 15 (09): : 2045 - +
  • [9] NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1
    Linda Ahammer
    Sarina Grutsch
    Michael Wallner
    Fatima Ferreira
    Martin Tollinger
    Biomolecular NMR Assignments, 2017, 11 : 231 - 234
  • [10] NMR resonance assignments of a hypoallergenic isoform of the major birch pollen allergen Bet v 1
    Ahammer, Linda
    Grutsch, Sarina
    Wallner, Michael
    Ferreira, Fatima
    Tollinger, Martin
    BIOMOLECULAR NMR ASSIGNMENTS, 2017, 11 (02) : 231 - 234
12345